“…Numerous pharmacological strategies have been employed to modulate conjunctival scarring. These include corticosteroids [ 2 ], antimitotics (5-fluorouracil, 5-FU and mitomycin C, MMC) [ 3 – 5 ], beta-radiation [ 6 , 7 ], inhibitors of growth factors (lederlimumab, bevacizumab) [ 8 , 9 ], and metalloproteinase inhibitors (ilomastat) [ 10 ]. However, some of these drugs are relatively nonspecific and lead to complications such as hypotony, endophthalmitis, etc.…”